IRIS
SCANDURRA, GIUSEPPA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.759
AS - Asia 1.035
EU - Europa 564
SA - Sud America 353
AF - Africa 33
OC - Oceania 4
Totale 3.748
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.712
SG - Singapore 403
BR - Brasile 275
HK - Hong Kong 220
IE - Irlanda 151
CN - Cina 139
VN - Vietnam 134
IT - Italia 126
DE - Germania 74
FR - Francia 55
GB - Regno Unito 42
AR - Argentina 40
IN - India 24
TR - Turchia 24
PL - Polonia 23
BD - Bangladesh 22
MX - Messico 22
CA - Canada 19
FI - Finlandia 18
EC - Ecuador 15
NL - Olanda 15
ZA - Sudafrica 13
AT - Austria 12
ID - Indonesia 11
IQ - Iraq 11
MA - Marocco 9
JP - Giappone 8
RU - Federazione Russa 8
SA - Arabia Saudita 7
UA - Ucraina 7
ES - Italia 6
SE - Svezia 6
CO - Colombia 5
CZ - Repubblica Ceca 5
PK - Pakistan 5
CL - Cile 4
KG - Kirghizistan 4
PY - Paraguay 4
BO - Bolivia 3
CH - Svizzera 3
KE - Kenya 3
TH - Thailandia 3
TN - Tunisia 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AU - Australia 2
LV - Lettonia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PE - Perù 2
PH - Filippine 2
SN - Senegal 2
UZ - Uzbekistan 2
VE - Venezuela 2
AZ - Azerbaigian 1
BE - Belgio 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GE - Georgia 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
JM - Giamaica 1
JO - Giordania 1
KH - Cambogia 1
KR - Corea 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
TZ - Tanzania 1
Totale 3.748
Salva come PNG Salva come JPEG
Città #
Dallas 845
Hong Kong 219
Singapore 201
San Jose 186
Dublin 151
Ashburn 126
The Dalles 76
Chicago 74
Ho Chi Minh City 57
Boardman 51
Beijing 46
Santa Clara 35
Hanoi 25
São Paulo 24
Warsaw 22
Los Angeles 20
Munich 20
Frankfurt am Main 18
Palermo 18
Assago 16
Istanbul 16
London 15
Milan 15
Helsinki 14
Mexico City 14
Rio de Janeiro 13
New York 11
Hillsboro 10
Atlanta 9
Chennai 8
Council Bluffs 8
Rome 8
Belo Horizonte 7
Haiphong 7
Quito 7
Amsterdam 6
Campinas 6
Düsseldorf 6
Fortaleza 6
Misilmeri 6
Stockholm 6
Tokyo 6
Agrigento 5
Baghdad 5
Biên Hòa 5
Catania 5
Dhaka 5
Jeddah 5
Johannesburg 5
Limburg an der Lahn 5
Manchester 5
Montreal 5
Mumbai 5
Portsmouth 5
Reston 5
San Francisco 5
Brasília 4
Brno 4
Brooklyn 4
Buenos Aires 4
Can Tho 4
Charlotte 4
Cologne 4
Curitiba 4
Guayaquil 4
Lauterbourg 4
Nuremberg 4
Orem 4
Salvador 4
Seattle 4
Toronto 4
Ankara 3
Asunción 3
Bishkek 3
Cape Town 3
Caselle Torinese 3
Colombo 3
Da Nang 3
Erbil 3
Joinville 3
Montevideo 3
Nairobi 3
Naples 3
Phoenix 3
Porto Alegre 3
Secaucus 3
Três Lagoas 3
Turku 3
Varallo Pombia 3
Zurich 3
Angra dos Reis 2
Aparecida de Goiânia 2
Aracaju 2
Athens 2
Auckland 2
Augusta 2
Bandung 2
Bangkok 2
Boston 2
Cabo Frio 2
Totale 2.641
Salva come PNG Salva come JPEG
Nome #
Management of ocular toxicity in patients with gynecologic cancer receiving novel antibody–drug conjugates: a narrative review 231
A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy 95
A Survey on the Prescribing Orientation Towards Complementary Therapies Among Oncologists in Italy: Symptoms and Unmet Patient Needs 86
A Narrative Review of the Role of Immunotherapy in Metastatic Carcinoma of the Colon Harboring a BRAF Mutation 81
A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer 80
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study 79
A Multicenter Real-Life Evaluation of Safety and Effectiveness of the Antibody-Drug Conjugate Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer 78
Efficacy and safety of neoadjuvant paclitaxel, ifosfamide, and cisplatin (TIP) chemotherapy in locally advanced squamous cell cervical carcinoma followed by radical surgery: A single institution experience 78
A review and metanalysis of metronomic oral single-agent cyclophosphamide for treating advanced ovarian carcinoma in the era of precision medicine 76
Brain Metastasis in Endometrial Cancer: A Systematic Review 73
Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma 69
Pomegranate: A promising avenue against the most common chronic diseases and their associated risk factors (Review) 66
Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study 64
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy 61
Identification of the novel BRCA1 c.2463_2464delTA mutation in two high grade serous ovarian cancer sisters and potential dosage effects implications: a case report 60
Comprehensive Axillary Management of Clinically Node-Positive (cN+) Breast Cancer Patients: A Narrative Review on Neoadjuvant Chemotherapy 60
Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay 59
Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2− Breast Cancer 58
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial 57
New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful? 57
Risk-reducing mastectomy in healthy women with BRCA mutation: a narrative review 57
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study 57
De-escalation of complexity in oncoplastic breast surgery: Case series from a specialized breast center 57
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity 54
A Survey on Knowledge and Attitudes Towards Vaccination Against Herpes Zoster Virus Among Medical Oncologists for Patients with Solid Tumors 54
Accuracy and Outcomes of Sentinel Lymph Node Biopsy in Male with Breast Cancer: A Narrative Review and Expert Opinion 53
Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy 53
Appropriate Management of Cutaneous Adverse Events Maximizes Compliance with Sorafenib Treatment: A Single-Center Experience 51
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial 51
Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial? 51
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status 50
Synergistic Immune-Mediated Anti-tumour Effect of Dostarlimab and Radiotherapy in the Management of MSI-H/dMMR Endometrial Cancer: A Case Report 50
Unusual presentation of luminal breast carcinoma metastatic to the brain and coma: a case report of dramatic response to abemaciclib and literature review 50
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)–Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors—A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study 49
Trabectedin maintenance therapy after liposomal doxorubicin plus trabectedin combination in patients with relapsed ovarian cancer: the randomized, phase II TRAMANT study 49
Immune checkpoint inhibitor therapy‑related pneumonitis: How, when and why to diagnose and manage (Review) 49
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors 48
Immune-checkpoint inhibitors from cancer to COVID‑19: A promising avenue for the treatment of patients with COVID‑19 (Review) 48
Correction: Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial 47
Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey 47
The long survival in oncology: which QoL? Finding study in more than five years after the end of treatment 46
Syringoid eccrine carcinoma of the vulva: differential diagnosis, treatment, and follow-up 46
The group's waiting room: groups of self-help in oncology 46
Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy 46
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer 45
Real-World Analysis of HRD Assay Variability in High-Grade Serous Ovarian Cancer: Impacts of BRCA1/2 Mutation Subtypes on HRD Assessment 45
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial 44
The Impact of Neoadjuvant Chemotherapy on Axillary Surgical Management of Patients With Breast Cancer and Positive Axillary Lymph Nodes 43
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study 42
European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma 42
Gynecological Cancer and Venous Thromboembolism: A Narrative Review to Increase Awareness and Improve Risk Assessment and Prevention 41
The Consistency and Quality of ChatGPT Responses Compared to Clinical Guidelines for Ovarian Cancer: A Delphi Approach 41
Phase II Study of the Effectiveness of the Germinated Wheat-derived Rigenase Plus Polyhexanide in the Prophylaxis for Hypofractionated Radiation-induced Acute Skin Toxicity in Breast Cancer 41
New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful? 40
Quality of Life in Women Diagnosed with Breast Cancer after a 12-Month Treatment of Lifestyle Modifications 39
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society 39
Safety and efficacy of new techniques of radiotherapy in oligometastatic recurrence ovarian cancer ( ROC) patients with BRCA 1/2 mutation. A monoistitutional experience 38
Unveiling the Intricate Dance: How Cancer Orchestrates Muscle Wasting and Sarcopenia 37
Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study. 36
Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance 35
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort 35
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study 35
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 34
Exploratory Analysis of Dunning–Kruger Effect Among Oncologists Managing Prostatic Adenocarcinoma Candidates for Radionuclide Therapy 31
Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial 30
Breast-Conserving Surgery in BRCA Mutation Carriers: A Paradigm Shift Toward Individualized, Multidisciplinary Care 29
Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice 28
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 28
Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis 26
Multidisciplinary team for elucidation of any new mutation and how this approach can be useful to individualize any genetic result: the case of BRCA2 c.631G>A/c.7008-2A>T genotype 25
The importance of planning a correct therapeutic strategy in patients with recurrent ovarian cancer. 24
Phase II Study of Gemcitabine and Cisplatin in Patients with Advanced or Metastatic Bladder Cancer: Long-Term Follow-Up of a 3-Week Regimen 24
PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey 17
Gynecological Cancer Patient Perspectives On The Impact Of Illness And On Clinical Research Awareness: A MITO Group Nationwide Italian Survey 12
A multidisciplinary approach and patient and caregiver education lead to improved prevention and rapid resolution of ocular adverse events in ovarian cancer patients treated with mirvetuximab soravtansine 12
Proper training of healthcare personnel helps to manage urgentemergency situations in an optimal way 10
Beyond the Goal (Lens) towards new mental spaces. 10
"Stay Stand" Project. Workshops in a Rugby field with cancer patients, their family and healthcare staff 8
Optimizing the management of therapies by providing a subcutaneous injection 8
Optimizing the management of peripherally inserted central catheter (PICC) 8
Quality of life in southern Italian women with gynecological cancer. 7
Totale 3.866
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.214
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.214
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20231 0 0 0 0 0 0 0 0 0 0 1 0
2023/2024213 1 2 13 10 24 16 34 21 14 18 26 34
2024/20251.049 40 17 30 8 61 131 110 100 127 153 149 123
2025/20262.603 186 519 574 269 138 86 189 248 249 145 0 0
Totale 3.866